TrovaGene Inc (NASDAQ:TROV)’s share price traded down 5.9% during trading on Thursday . The stock traded as low as $0.31 and last traded at $0.32. 979,066 shares traded hands during trading, a decline of 41% from the average session volume of 1,648,776 shares. The stock had previously closed at $0.34.
Several equities analysts recently commented on the stock. Maxim Group set a $4.00 target price on shares of TrovaGene and gave the company a “buy” rating in a report on Wednesday, October 18th. lowered shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. ValuEngine raised shares of TrovaGene from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, HC Wainwright assumed coverage on shares of TrovaGene in a report on Thursday, December 21st. They set a “buy” rating and a $1.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $3.70.
The stock has a market capitalization of $26.16, a price-to-earnings ratio of -0.41 and a beta of 0.26.
An institutional investor recently raised its position in TrovaGene stock. Susquehanna International Group LLP lifted its stake in TrovaGene Inc (NASDAQ:TROV) by 254.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 488,937 shares of the medical research company’s stock after purchasing an additional 350,906 shares during the period. Susquehanna International Group LLP owned 1.28% of TrovaGene worth $357,000 as of its most recent SEC filing. 9.87% of the stock is currently owned by hedge funds and other institutional investors.
TrovaGene Company Profile
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.